6 results on '"Karberg, Kirsten"'
Search Results
2. Persistent but atypical germinal center reaction among 3rd SARS-CoV-2 vaccination after rituximab exposure
- Author
-
Stefanski, Ana-Luisa, primary, Rincon-Arevalo, Hector, additional, Schrezenmeier, Eva, additional, Karberg, Kirsten, additional, Szelinski, Franziska, additional, Ritter, Jacob, additional, Chen, Yidan, additional, Meisel, Christian, additional, Jahrsdörfer, Bernd, additional, Ludwig, Carolin, additional, Schrezenmeier, Hubert, additional, Lino, Andreia C., additional, and Dörner, Thomas, additional
- Published
- 2022
- Full Text
- View/download PDF
3. B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients
- Author
-
Stefanski, Ana-Luisa, primary, Rincon-Arevalo, Hector, additional, Schrezenmeier, Eva, additional, Karberg, Kirsten, additional, Szelinski, Franziska, additional, Ritter, Jacob, additional, Chen, Yidan, additional, Jahrsdörfer, Bernd, additional, Ludwig, Carolin, additional, Schrezenmeier, Hubert, additional, Lino, Andreia C., additional, and Dörner, Thomas, additional
- Published
- 2022
- Full Text
- View/download PDF
4. B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients
- Author
-
Stefanski, Ana-Luisa, Rincon-Arevalo, Hector, Schrezenmeier, Eva, Karberg, Kirsten, Szelinski, Franziska, Ritter, Jacob, Chen, Yidan, Jahrsdörfer, Bernd, Ludwig, Carolin, Schrezenmeier, Hubert, Lino, Andreia C., and Dörner, Thomas
- Subjects
SARS-CoV-2 ,Immunology ,Vaccination ,B-cells ,COVID-19 ,prediction ,Arthritis, Rheumatoid ,Immunoglobulin G ,Immunology and Allergy ,SARS – CoV – 2 ,Humans ,RTX (rituximab) ,Rituximab ,600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit - Abstract
Background: Vaccination is considered as most efficient strategy in controlling SARS-CoV-2 pandemic spread. Nevertheless, patients with autoimmune inflammatory rheumatic diseases receiving rituximab (RTX) are at increased risk to fail humoral and cellular responses upon vaccination. The ability to predict vaccination responses is essential to guide adequate safety and optimal protection in these patients. Methods: B- and T- cell data before vaccination were evaluated for characteristics predicting vaccine responses in altogether 15 patients with autoimmune inflammatory rheumatic diseases receiving RTX. Eleven patients with rheumatoid arthritis (RA) on other therapies, 11 kidney transplant recipients (KTR) on regular immunosuppression and 15 healthy controls (HC) served as controls. A multidimensional analysis of B cell subsets via UMAP algorithm and a correlation matrix were performed in order to identify predictive markers of response in patients under RTX therapy. Results: Significant differences regarding absolute B cell counts and specific subset distribution pattern between the groups were identified at baseline. In this context, the majority of B cells from vaccination responders of the RTX group (RTX IgG+) were naïve and transitional B cells, whereas vaccination non-responders (RTX IgG-) carried preferentially plasmablasts and double negative (CD27-IgD-) B cells. Moreover, there was a positive correlation between neutralizing antibodies and B cells expressing HLA-DR and CXCR5 as well as an inverse correlation with CD95 expression and CD21low expression by B cells among vaccination responders. Summary: Substantial repopulation of the naïve B cell compartment after RTX therapy appeared to be essential for an adequate vaccination response, which seem to require the additional capability of antigen presentation and germinal center formation. Moreover, expression of exhaustion markers represent negative predictors of vaccination responses.
- Published
- 2021
5. Persistent but atypical germinal center reaction among 3rd SARS-CoV-2 vaccination after rituximab exposure.
- Author
-
Stefanski, Ana-Luisa, Rincon-Arevalo, Hector, Schrezenmeier, Eva, Karberg, Kirsten, Szelinski, Franziska, Ritter, Jacob, Yidan Chen, Meisel, Christian, Jahrsdörfer, Bernd, Ludwig, Carolin, Schrezenmeier, Hubert, Lino, Andreia C., and Dörner, Thomas
- Subjects
GERMINAL centers ,IMMUNOLOGIC memory ,RITUXIMAB ,VACCINATION ,PLASMA cells ,HYPERCOAGULATION disorders - Abstract
Background: Durable vaccine-mediated immunity relies on the generation of long-lived plasma cells and memory B cells (MBCs), differentiating upon germinal center (GC) reactions. SARS-CoV-2 mRNA vaccination induces a strong GC response in healthy volunteers (HC), but limited data is available about response longevity upon rituximab treatment. Methods: We evaluated humoral and cellular responses upon 3rd vaccination in seven patients with rheumatoid arthritis (RA) who initially mounted anti-spike SARS-CoV-2 IgG antibodies after primary 2x vaccination and got re-exposed to rituximab (RTX) 1-2 months after the second vaccination. Ten patients with RA on other therapies and ten HC represented the control groups. As control for known long-lived induced immunity, we analyzed humoral and cellular tetanus toxoid (TT) immune responses in steady-state. Results: After 3rd vaccination, 5/7 seroconverted RTX patients revealed lower anti-SARS-CoV-2 IgG levels but similar neutralizing capacity compared with HC. Antibody levels after 3rd vaccination correlated with values after 2nd vaccination. Despite significant reduction of circulating total and antigenspecific B cells in RTX re-exposed patients, we observed the induction of IgG+ MBCs upon 3rd vaccination. Notably, only RTX treated patients revealed a high amount of IgA+ MBCs before and IgA+ plasmablasts after 3rd vaccination. IgA+ B cells were not part of the steady state TT+ B cell pool. TNF-secretion and generation of effector memory CD4 spike-specific T cells were significantly boosted upon 3rd vaccination. Summary: On the basis of pre-existing affinity matured MBCs within primary immunisation, RTX re-exposed patients revealed a persistent but atypical GC immune response accompanied by boosted spike-specific memory CD4 T cells upon SARS-CoV-2 recall vaccination. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. Persistent but atypical germinal center reaction among 3 rd SARS-CoV-2 vaccination after rituximab exposure.
- Author
-
Stefanski AL, Rincon-Arevalo H, Schrezenmeier E, Karberg K, Szelinski F, Ritter J, Chen Y, Meisel C, Jahrsdörfer B, Ludwig C, Schrezenmeier H, Lino AC, and Dörner T
- Subjects
- Antibodies, Viral, COVID-19 Vaccines, Germinal Center, Humans, Immunoglobulin A, Immunoglobulin G, Rituximab, SARS-CoV-2, Vaccination, Arthritis, Rheumatoid, COVID-19
- Abstract
Background: Durable vaccine-mediated immunity relies on the generation of long-lived plasma cells and memory B cells (MBCs), differentiating upon germinal center (GC) reactions. SARS-CoV-2 mRNA vaccination induces a strong GC response in healthy volunteers (HC), but limited data is available about response longevity upon rituximab treatment., Methods: We evaluated humoral and cellular responses upon 3rd vaccination in seven patients with rheumatoid arthritis (RA) who initially mounted anti-spike SARS-CoV-2 IgG antibodies after primary 2x vaccination and got re-exposed to rituximab (RTX) 1-2 months after the second vaccination. Ten patients with RA on other therapies and ten HC represented the control groups. As control for known long-lived induced immunity, we analyzed humoral and cellular tetanus toxoid (TT) immune responses in steady-state., Results: After 3
rd vaccination, 5/7 seroconverted RTX patients revealed lower anti-SARS-CoV-2 IgG levels but similar neutralizing capacity compared with HC. Antibody levels after 3rd vaccination correlated with values after 2nd vaccination. Despite significant reduction of circulating total and antigen-specific B cells in RTX re-exposed patients, we observed the induction of IgG+ MBCs upon 3rd vaccination. Notably, only RTX treated patients revealed a high amount of IgA+ MBCs before and IgA+ plasmablasts after 3rd vaccination. IgA+ B cells were not part of the steady state TT+ B cell pool. TNF-secretion and generation of effector memory CD4 spike-specific T cells were significantly boosted upon 3rd vaccination., Summary: On the basis of pre-existing affinity matured MBCs within primary immunisation, RTX re-exposed patients revealed a persistent but atypical GC immune response accompanied by boosted spike-specific memory CD4 T cells upon SARS-CoV-2 recall vaccination., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Stefanski, Rincon-Arevalo, Schrezenmeier, Karberg, Szelinski, Ritter, Chen, Meisel, Jahrsdörfer, Ludwig, Schrezenmeier, Lino and Dörner.)- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.